Results for: MeiraGTx

Jim Cramer, the renowned host of CNBC’s ‘Mad Money,’ shared his insights on three companies during his Lightning Round segment. Cramer recommended buying shares of Jabil Inc. (JBL), praising the company’s strong performance and share buyback program. He advised caution regarding MeiraGTx Holdings plc (MGTX), suggesting investors speculate on its potential but be prepared for the possibility of limited returns. Meanwhile, Cramer expressed optimism about SoFi Technologies, Inc. (SOFI), highlighting its impressive third-quarter earnings and revenue growth.

MeiraGTx Holdings’ (MGTX) gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) has shown positive results in a clinical bridging study, meeting its primary objective of safety and tolerability. The study also demonstrated significant improvements in key efficacy endpoints, leading to a 14.9% surge in MGTX’s stock price. This promising development could pave the way for a potential phase III study and global approval of this disease-modifying treatment.

MeiraGTx Holdings plc (MGTX) announced positive topline data from its clinical bridging study of AAV-GAD for Parkinson’s disease, showing significant improvements in motor function and quality of life for patients in the high-dose group. The gene therapy was found to be safe and well-tolerated, with no serious adverse events related to the treatment.